Cargando…
Adoptive Cell Therapies for Glioblastoma
Glioblastoma (GBM) is the most common and most aggressive primary brain malignancy and, as it stands, is virtually incurable. With the current standard of care, maximum feasible surgical resection followed by radical radiotherapy and adjuvant temozolomide, survival rates are at a median of 14.6 mont...
Autores principales: | Bielamowicz, Kevin, Khawja, Shumaila, Ahmed, Nabil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823029/ https://www.ncbi.nlm.nih.gov/pubmed/24273748 http://dx.doi.org/10.3389/fonc.2013.00275 |
Ejemplares similares
-
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma
por: Wang, Jingyu, et al.
Publicado: (2020) -
Human Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy
por: Landi, Daniel, et al.
Publicado: (2014) -
CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020) -
Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023) -
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
por: Mullinax, John E., et al.
Publicado: (2018)